Abstracts tagged "Epidemiologic methods"

Abstract Number: 2067 • 2014 ACR/ARHP Annual Meeting
Understanding the Factors Influencing Time to Diagnosis in Fibromyalgia
Howard Amital¹, Yaeli Bar-On², Varda Shalev³, Dahlia Weitzman³ and Gabriel Chodick⁴, ¹Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, ²Department of Medicine E,, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ³Medical Informatics, Maccabi Healthcare Services, Tel Aviv, Tel-Aviv, Israel, ⁴Medical Informatics, Healthcare Services, Tel Aviv, Tel-Aviv, Israel
Background/Purpose - Fibromyalgia (FM) is a chronic debilitating disorder considered to be part of a spectrum of central sensitization syndromes. The diagnosis of FM is…
Abstract Number: 623 • 2014 ACR/ARHP Annual Meeting
Epigenetic Studies in Maternally Versus Paternally Transmitted Psoriatic Disease
Darren D. O'Rielly¹, Remy Pollock², Yuhua Zhang³, Nayef Al Ghanim¹, Sean Hamilton¹, Dafna D. Gladman², Vinod Chandran², Rose Ardern¹, Guangju Zhai³ and Proton Rahman¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada
Background/Purpose: Epidemiological studies have noted excess paternal transmission in psoriasis and psoriatic arthritis. To date, there has been no molecular explanation to account for this…
Abstract Number: 2039 • 2014 ACR/ARHP Annual Meeting
Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects
Alfonse T. Masi, Azeem A. Rehman and Jean C. Aldag, Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Dysregulations in androgenic-anabolic (A-A) steroids and cytokines are recognized in RA and pre-RA subjects (Rheum Dis Clin N Am 2005; 31: 131-60). However, deviations…
Abstract Number: 480 • 2014 ACR/ARHP Annual Meeting
Serious Infection Risk By Treatments and Types in Patients with RA
Kaleb Michaud^1,2, Sofia Pedro¹, Andre Kalil³, Ted R. Mikuls⁴ and Frederick Wolfe¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent studies provide conflicting results on the impact of DMARDs on the risk of serious infections for patients with RA. We examined these infection…
Abstract Number: 2038 • 2014 ACR/ARHP Annual Meeting
Respiratory Cause Mortality Was Significantly Predicted By Incident Rheumatoid Arthritis (RA) and Higher Pre-RA Levels (0.50+ SD) of Soluble Interleukin-2 Receptor Alpha (sIL-2Rá): Results of a 21-Year Community-Based Cohort Survival Analysis
Alfonse T. Masi¹, Azeem Rehman¹, Huaping Wang¹ and Jean Aldag², ¹Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, ²Medicine, University of Illinois College of Medicince at Peoria, retired, Peoria, IL
Background/Purpose: Interstitial lung disease (ILD) mortality is reported to be increased in RA (Bongartz T et al. A&R 2010; 62: 1583-91). However, non-malignant respiratory mortality…
Abstract Number: 358 • 2014 ACR/ARHP Annual Meeting
Parity and Severity of ACPA-Positive/Negative Rheumatoid Arthritis. Results from the Swedish EIRA Study
Mitra Pikwer¹, Cecilia Orellana², Henrik Källberg², Andreas Pikwer³, Carl Turesson⁴, Lars Klareskog⁵, Lars Alfredsson^6,7, Saedis Saevarsdottir⁸ and Camilla Bengtsson⁹, ¹Rheumatology Unit, Mälarhospital, Institute of Environmental Medicine, Eskilstuna, Sweden, ²Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Centre of Clinical Research Sörmland, Eskilstuna, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Malmö, Sweden, ⁵Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska institutet, Stockholm, Sweden, ⁶Institute of Environmental Medicine, Stockholm, Sweden, ⁷Centre of Occupational and Environmental Medicine, Stockholm, Sweden, ⁸Institute of Environmental Medicine, Karolinska Institutet,, Stockholm, Sweden, ⁹The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose Female sex and older age are known risk factors for rheumatoid arthritis (RA). The disease is however heterogeneous, and a common division occurs between…
Abstract Number: 2022 • 2014 ACR/ARHP Annual Meeting
First Nations Persons Have an Increased Risk of Developing Rheumatoid Arthritis with an Early Onset Age but Are Seen Less Frequently By Rheumatologists: A Population Based Study
Carol A. Hitchon¹, Sazzadul Khan², Brenda Elias³, Hani S. El-Gabalawy⁴, Alan Katz⁵ and Christine A. Peschken¹, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²Manitoba Centre for Health Policy and Research, University of Manitoba, Winnipeg, MB, Canada, ³Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁴Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada
Background/Purpose High global prevalence rates of rheumatoid arthritis (RA) have been reported in First Nations (FN). For our regional population of 1.2 million, health care…
Abstract Number: 234 • 2014 ACR/ARHP Annual Meeting
The Decrease in Prescription of Anti-Osteoporotic Drugs Has No Impact on Hip Fracture Incidence
Karine Briot¹, Milka Maravic² and Christian Roux³, ¹Cochin Hospital, Paris Descartes University, Paris, France, ²Hopital Leopold Bellan, Paris, France, ³Paris Descartes University, Cochin Hospital, Paris, France
Background/Purpose Controversies exist about the change in hip fracture incidence among countries. In France, we previously showed that the incidence of hip fractures decreased in…
Abstract Number: 2015 • 2014 ACR/ARHP Annual Meeting
Fine Particulate Air Pollution and Systemic Autoimmune Rheumatic Disease in Two Canadian Provinces
Sasha Bernatsky¹, Audrey Smargiassi², Cheryl Barnabe³, Lawrence W. Svenson⁴, Allan Brand⁵, Marie Hudson⁶, Steven M. Edworthy⁷, Ann E. Clarke³, Paul R. Fortin⁸, Patrick Belisle⁹ and Lawrence Joseph¹⁰, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Département de santé environnementale et santé au travail, Université de Montréal, Montréal, QC, Canada, ³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁴Community Health Sciences, University of Calgary, Calgary, AB, Canada, ⁵Institut national de santé publique du Québec, Montreal, QC, Canada, ⁶Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁷The University of Calgary, Calgary, AB, Canada, ⁸Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ⁹Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada
Background/Purpose: To estimate the degree to which fine particulate (PM2.5) air pollution is associated with systemic autoimmune rheumatic diseases (SARDs). Methods: We used population-based administrative…
Abstract Number: 59 • 2014 ACR/ARHP Annual Meeting
Assessing Dietary Habits in a Large Cohort of Rheumatoid Arthritis and Psoriatic Arthritis Patients: Results of the Spanish Imid Consortium
Maria López Lasanta¹, Jesús Tornero², Juan D. Cañete³, Antonio Fernandez Nebro⁴, Francisco Blanco⁵, Jesus Rodriguez⁶, Isidoro González-Alvaro⁷, Jordi Gratacós⁸, Joan Maymo⁹, Rubén Queiro¹⁰, Mercedes Alperi-López¹¹, Carlos Montilla-Morales¹², Benjamin Fernandez Gutierrez¹³, Juan Carlos Torre-Alonso¹⁴, Alejandro Olive¹⁵, Jose Javier Perez Venegas¹⁶, Hector Corominas¹⁷, Alba Erra¹⁸, Santiago Muñoz¹⁹, Carlos M. Gonzalez²⁰, Daniel Roig²¹, Gabriela Avila¹, Arnald Alonso¹, Toni Julia¹, Raül Tortosa¹, Andrés Garcia Montero²² and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Hospital Universitario Guadalajara, Guadalajara, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ⁵Complejo Hospitalario Juan Canalejo, A Coruña, Spain, ⁶Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁸Hospital Parc Taulí, Sabadell, Spain, ⁹Rheumatology, Hospital del Mar, Barcelona, Spain, ¹⁰Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ¹¹Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹²H. de Salamanca, Salamanca, Spain, ¹³Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ¹⁴Rheumatology Department, H. Monte Naranco, Oviedo, Spain, ¹⁵Rheumatology Service, Germans Trias Pujol Hospital, Barcelona, Spain, ¹⁶Rheumatology Department, Hospital del SAS Jerez de la Frontera, Cadiz, Spain, ¹⁷Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁸Rheumatology Department, Hospital Sant Rafael, Barcelona, Spain, ¹⁹Rheumatology Department, Hospital Infanta Sofia, Madrid, Spain, ²⁰Rheumatology Department, Gregorio Marañon Hospital, Madrid, Spain, ²¹Rheumatology Service, Hospital Moisès Broggi,, Barcelona, Spain, ²²Banco Nacional de ADN, Salamanca, Spain
Background/Purpose: Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA) are complex diseases of unknown etiology and its pathogenesis results from the combination of genetic susceptibility and…
Abstract Number: 1877 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes in SLE: Before and after
Elizabeth V. Arkema¹, Kristin Palmsten², Christopher Sjöwall³, Elisabet Svenungsson⁴, Jane E. Salmon⁵ and Julia F Simard⁶, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Pediatrics, University of California, San Diego, La Jolla, CA, ³Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA
Background/Purpose: Numerous investigators have demonstrated that the risks of pre-eclampsia, preterm delivery, and fetal death are increased in lupus pregnancies. Adverse events during pregnancy, delivery,…
Abstract Number: 65 • 2014 ACR/ARHP Annual Meeting
Impact of Dropout and Total Knee Replacement on Joint Space Narrowing Estimation: Data from Osteoarthritis Initiaive
Jamie E. Collins and Elena Losina, Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA
Impact of dropout and TKR on Joint Space Narrowing estimation: data from Osteoarthritis InitiativeBackground/Purpose: Structural progression in knee osteoarthritis (OA) is often measured by Joint…
Abstract Number: 1874 • 2014 ACR/ARHP Annual Meeting
Obesity Paradox in Recurrent Gout – a Metrological Clarification and Remedy
Uyen Sa D.T. Nguyen^1,2, Qiong Louie-Gao³, Yuqing Zhang⁴, David T. Felson³, Michael P. Lavalley⁵ and Hyon K. Choi⁶, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²Clinical Epidemiology Research &Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Biostatistics, Boston University, Boston, MA, ⁶Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Obesity is a strong risk factor of incident gout, but previous research showed no such association with recurrent gout among gout patients. These paradoxical…
Abstract Number: 49 • 2014 ACR/ARHP Annual Meeting
Long-Term Oral Bisphosphonate Use for Osteoporosis Among Older Women – US and Canadian Perspective
Nicole C. Wright¹, Wilson Smith², Amy H. Warriner³, Jeff Foster⁴, Ruth McConnell⁵, Huifeng Yun⁶, Mary H Melton⁷, Jeffrey R. Curtis⁴ and Kenneth G. Saag⁸, ¹Epidemiology, The University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁷Medicine, The University of Alabama at Birmingham, Birmingham, AL, ⁸Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Bisphosphonates (BPs) have been widely used for the treatment and prevention of osteoporosis for two decades. Although new parenteral preparations have been introduced, oral…
Abstract Number: 1670 • 2014 ACR/ARHP Annual Meeting
Characterization of Patients with Lupus Nephritis Included in a Large Cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus
María Galindo Izquierdo¹, Esther Rodriguez-Almaraz¹, Sabina Perez², José M. Pego-Reigosa³, Jaime Calvo-Alen⁴, Francisco Javier López-Longo⁵, Iñigo Rúa-Figueroa⁶, Alejandro Olivé⁷, Víctor Martínez Taboada⁸, Paloma Vela Casasempere⁹, Mercedes Freire¹⁰, Javier Narváez¹¹, Antonio Fernandez Nebro¹², Jose Rosas¹³, Monica Ibanez Barcelo¹⁴, Esther Uriarte¹⁵, Eva Tomero¹⁶, Antonio Zea¹⁷, Maria Loreto Horcada¹⁸, Vicente Torrente¹⁹, Ivan Castellvi²⁰, Joan Calvet²¹, Raúl Menor Almagro²², Mª Angeles Aguirre²³, Enrique Raya²⁴, Elvira Diez Alvarez²⁵, Tomás Vázquez Rodríguez²⁶, Paloma García de la Peña²⁷, Atusa Movasat²⁸, José Luis Andreu²⁹, Patricia Richi³⁰, Carlos Marras Fernandez-Cid³¹, Carlos Alberto Montilla Morales³², Blanca Hernández-Cruz³³, José Luis Marenco de la Fuente³⁴, Marian Gantes³⁵, Eduardo Ucar³⁶, Juan J. Alegre³⁷, Javier Manero³⁸, Jesús Ibañez Ruán³⁹, Manuel Rodríguez-Gómez⁴⁰, Victor Quevedo⁴¹, José Hernández Beiraín⁴² and Lucía Silva Fernández⁴³, ¹Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ²Sociedad Española de Reumatología, Research Unit,, Madrid, Spain, ³Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Hospital Gregorio Marañon, Rheumatology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Rheumatology, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁷Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology, Marqués de Valdecilla, Santander, Spain, ⁹Hospital General de Alicante, Alicante, Spain, ¹⁰Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹¹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ¹²Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ¹³Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ¹⁴H. Son Llatzer, Palma de Mallorca, Spain, ¹⁵Rheumatology, Hospital de Donosti, San Sebastian, Spain, ¹⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁸Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁹Rheumatology, Hospital Moisès Broggi, Barcelona, Spain, ²⁰Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²¹Hospital Parc Taulí, Barcelona, Spain, ²²Rheumatology, Hospital de Jerez, Jerez de la Frontera, Spain, ²³Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ²⁴Rheumatology, University Hospital San Cecilio, Granada, Spain, ²⁵Rheumatology, Leon Hospital, Leon, Spain, ²⁶Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ²⁷Rheumatology, Hospital Norte Sanchinarro, Madrid, Spain, ²⁸Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, ²⁹Rheumatology, Hospital Puerta de Hierro, Madrid, Spain, ³⁰Hospital Infanta Sofía, Madrid, Spain, ³¹C/ Salvia 11, H. Arrixaca, Alicante, Spain, ³²Rheumatology Department, Hospital Virgen de la Vega, Salamanca, Spain, ³³Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ³⁴Hospital de Valme. Sevilla, Sevilla, Spain, ³⁵Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ³⁶Hospital de Basurto, Rheumatology, Bilbao, Spain, ³⁷Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ³⁸Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ³⁹POVISA, Rheumatology, Vigo, Spain, ⁴⁰Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴¹Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴²Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ⁴³Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain
Background/Purpose To describe the profile of patients included in RELESSER with histologically confirmed lupus nephritis (LN). Methods RELESSER is a multicentre cross-sectional study, with information…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].